Satsuma Pharmaceuticals Analysis
What is Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals develops innovative therapeutics for acute migraine treatment, focusing on STS101, a dihydroergotamine nasal powder.
Founded
2016
Company Stage
Other
YC Batch
S21
Product Features & Capabilities
- STS101, Dihydroergotamine (DHE) Nasal Powder, Acute treatment of migraine with or without aura, Investigational product, Not yet FDA approved.
Who are the founders of Satsuma Pharmaceuticals
Investors
- TPG
- Vivo Capital
- CAM Capital
- Citadel Enterprise Americas
- Commodore Capital
- Cormorant Asset Management
- 16 other unnamed investors
See something that needs updating? Suggest edits to this profile.